swertiamarin and Metabolic-Syndrome

The herbal plant extract of Enicostemma littorale is widely used to medicate and treat type II Diabetes. This extract in medicine has shown its value in reducing blood glucose & lipid levels, and improving the kidney functioning, lipid profile, controlling blood pressure and heart rate. The well characterized chemical components such as iridoid and secoiridoid glycosides are present in aqueous and ethanolic extracts of the plant. Swertiamarin, a secoiridoid glycoside, is identified as the lead compound that confers anti-hyperglycemic & anti-hyperlipidemic effects. The swertiamarin binds with one or more molecular targets to alter their expression and/or activity. The in silico, in vivo and in vitro studies have been carried out to uncover the underlying molecular mechanism of action of swertiamarin and its derivatives for showing the better anti-diabetic & anti-hyperlipidemic activities. In brief, the present review focuses on unraveling the information about molecular targets of swertiamarin. Our review will open new avenues to develop therapeutic approaches and drugs to treat diabetes and other inflammatory diseases.

Topics: Animals; Computer Simulation; Diabetes Mellitus, Type 2; Disease Models, Animal; Gentianaceae; Glucose; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Iridoid Glucosides; Lipid Metabolism; Metabolic Networks and Pathways; Metabolic Syndrome; Molecular Targeted Therapy; Pyrones; Signal Transduction; Structure-Activity Relationship